EMBLAVEO^®
(aztreonam and avibactam)
PFIZER
HK Reg. No. HK-68891 (03 Nov, 2025)

Composition:¹

• Each vial contains 1.5 g aztreonam and avibactam sodium equivalent to 0.5 g avibactam
• After reconstitution, 1 mL of solution contains 131.2 mg of aztreonam and 43.7 mg of avibactam

Indication:¹

Emblaveo^® is indicated for the treatment of the following infections in adult patients:
• Complicated intra-abdominal infection (cIAI)
• Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP)
• Complicated urinary tract infection (cUTI), including pyelonephritis
Emblaveo^® is also indicated for the treatment of infections due to aerobic Gram-negative organisms in
adult patients with limited treatment options

References
1. EMA. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/emblaveo-eparproduct-information_en.pdf. [Accessed 23 December 2025].